Trusted Scientific Resources on Rare Diseases Research

At Travere Global Medical Affairs, we are dedicated to scientific exchange, including sharing up-to-date RKD scientific insights and resources with healthcare professionals.

The goal is to provide educational resources ranging from publications and expert-led podcasts to recent congress data and relevant medical information.

About us

Risk Evaluation and Mitigation Strategies (REMS) Update for Sparsentan

On August 27, 2025, the Risk Evaluation and Mitigation Strategies (REMS) requirements for sparsentan were updated to reduce the frequency of liver function monitoring to every three months and to remove the embryo-fetal toxicity REMS monitoring requirement.

For more information, please read the US Prescribing Information.

Read now

MA-SP-25-0127 | September 2025

62nd European Renal Association (ERA) Congress

The theme of the ERA 2025 Congress was “Game Changers in Nephrology.” Travere Therapeutics was excited to participate in the event and engage with renal healthcare professionals.

Learn more

MA-DS-25-0003 | May 2025

Webinar

A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan

Travere Therapeutics and the International Society of Nephrology (ISN) bring you a webinar on the place of sparsentan in the evolving therapeutic landscape of IgA nephropathy

Learn more

MA-SP-25-0013 | March 2025

Travere at NKF 2025

National Kidney Foundation (NKF) Spring Clinical Meetings 2025

The Spring Clinical Meetings (SCM) is the premiere educational event presented by the National Kidney Foundation (NKF). Travere Therapeutics was excited to participate in the event and engage with renal healthcare professionals.

Learn more

MA-DS-25-0001 | February 2025

Explore our science

Publication NephrologyIgAN

Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry

Kidney Medicine – 2025

Publication NephrologyFSGS

The Humanistic Burden of Focal Segmental Glomerulosclerosis on Patients and Care‑Partners in the United States

Quality of Life Research

Publication NephrologyFSGS

Population Risk Predictors of Major Adverse Kidney Events Attributed to Focal Segmental Glomerulosclerosis from the CURE-CKD Registry

BMC Nephrology

Publication NephrologyFSGS

Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria

Journal of the American Society of Nephrology

See all publications

Congress material NephrologyIgAN

Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study

Congress Name – 2025

Congress material NephrologyIgAN

Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial

Congress material NephrologyIgAN

Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial

Congress material FSGS

Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX

See all posters & presentations

Podcast Episode NephrologyFSGS

From Podocyte to Patient:
The Pathophysiology of FSGS

In this episode, Drs. Tobias Huber and Chris Gisler take a deep dive into the critical role of podocytes in maintaining glomerular function and their central involvement in the development and progression of FSGS.

Listen now

MA-SP-25-0077 | May 2025